You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康辰藥業(603590.SH):上海康辰完成密蓋息資產收購項目第三期轉讓款3.6億元的支付
格隆匯 07-06 17:02

格隆匯7月6日丨康辰藥業(603590.SH)公吿,此前,公司擬通過二級子公司康辰生物醫藥(上海)有限公司(“上海康辰”)以支付現金的方式收購經過業務重組後的泰凌醫藥國際有限公司(“泰凌國際”)100%股權,以實現對密蓋息資產的收購。

收購完成後,中國泰凌醫藥集團有限公司的下屬子公司泰凌醫藥(亞洲)有限公司(“泰凌亞洲”)以人民幣36,000萬元認購公司子公司北京康辰生物科技有限公司(“康辰生物”,即上海康辰的股東)新增註冊資本人民幣4,000萬元,取得康辰生物增資後40%的股權。

公司作為康辰生物原股東同意放棄本次增資優先認購權。增資完成以後,康辰生物的註冊資本由6,000萬元增加至10,000萬元,公司和泰凌亞洲持有康辰生物的股權比例分別為60%和40%。康辰生物已完成上述事項的工商變更登記手續並取得營業執照,泰凌亞洲已將其持有的康辰生物40%股權質押給公司。

截至2021年7月6日,上海康辰已按協議約定完成密蓋息資產收購項目第三期股份轉讓款人民幣3.6億元(該款項專項用於泰凌亞洲認購康辰生物新增註冊資本的出資義務)的支付,泰凌亞洲已按協議約定完成向康辰生物增資款的繳納。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account